{
  "source": "PA-Med-Nec-Caplyta.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 2208-6\nProgram Prior Authorization/Medical Necessity\nMedication Caplyta® (lumateperone)\nP&T Approval Date 6/2020, 7/2021, 3/2022, 6/2022, 11/2023, 11/2024\nEffective Date 2/1/2025\n1. Background:\nCaplyta is FDA approved for the treatment of schizophrenia and for depressive episodes associated\nwith bipolar I or II disorder as monotherapy and as adjunctive therapy with lithium or valproate in\nadults. This program requires a member to try three atypical antipsychotics for schizophrenia or two\natypical antipsychotics for bipolar depression before providing coverage for Caplyta.\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Caplyta will be approved based on ONE of the following criteria:\na. BOTH of the following:\n1) Diagnosis of schizophrenia\n-AND-\n2) History of failure, contraindication, or intolerance to three of the following (please\ndocument drug, date and duration of trial):\n(a) aripiprazole (generic Abilify)\n(b) olanzapine (generic Zyprexa)\n(c) quetiapine IR or ER (generic Seroquel or Seroquel XR)\n(d) risperidone (generic Risperdal)\n(e) ziprasidone (generic Geodon)\n-OR-\nb. BOTH of the following:\n1) Diagnosis of depressive episodes associated with bipolar I or II disorder (bipolar\ndepression)\n-AND-\n© 2024 UnitedHealthcare Services, Inc.\n1\n2) History of failure, contraindication, or intolerance to both of the following (please\ndocument date and duration of trial):\n(a) olanzapine (generic Zyprexa) in combination with an SSRI (e.g. fluoxetine)\n(b) quetiapine IR or ER (generic Seroquel or Seroquel XR)\n-OR-\nc. Treatment with Caplyta was initiated at a recent behavioral inpatient admission\n(discharge within the past 3 months) and the member is currently stable on therapy.\n(Please document date of discharge from inpatient admission).\n-OR-\nd. Member is new to the plan and currently stabilized on Caplyta (as evidenced by\ncoverage effective date of less than or equal to 120 days)\nAuthorization will ",
    "scharge from inpatient admission).\n-OR-\nd. Member is new to the plan and currently stabilized on Caplyta (as evidenced by\ncoverage effective date of less than or equal to 120 days)\nAuthorization will be issued for 12 months.\nB. Reauthorization\n1. Caplyta will be approved for continuation of therapy based on the following criterion:\na. Documentation of a positive clinical response to therapy\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n3. Additional Clinical Programs:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits and Prior Authorization/Notification may also be in place.\n4. References:\n1. Caplyta [package insert]. New York, NY: Intra-Cellular Therapies, Inc. June 2023.\n2. American Psychiatric Association. Practice Guideline for the Treatment of Patients with\nSchizophrenia Third Edition. Available at:\nhttps://psychiatryonline.org/doi/10.1176/appi.books.9780890424841\n3. American Psychiatric Association. Practice Guideline for the Treatment of Patients with Bipolar\nDisorder Second Edition. Available at:\nhttps://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/bipolar.pdf\n© 2024 UnitedHealthcare Services, Inc.\n2\nProgram Prior Authorization/Medical Necessity - Caplyta (lumateperone)\nChange Control\n6/2020 New program.\n7/2021 Annual review. Updated references and added continuation of therapy\ncoverage criteria.\n3/2022 Updated to include coverage for depressive episodes associated with\nbipolar disorder due to new labeling.\n6/2022 Modified criteria for bipolar depression. Updated references.\n11/2",
    "age criteria.\n3/2022 Updated to include coverage for depressive episodes associated with\nbipolar disorder due to new labeling.\n6/2022 Modified criteria for bipolar depression. Updated references.\n11/2023 Updated references.\n11/2024 Annual review with no changes.\n© 2024 UnitedHealthcare Services, Inc.\n3"
  ]
}